What is claimed is:

1. A compound having the structure:



wherein

R_1, R_2, R_3, R_4, and R_5 are each independently H, halogen, CF_3 or C_1-C_4 alkyl,

wherein two or more of R_1, R_2, R_3, R_4, or R_5 are other than H;

R_6 is H, OH, or halogen; and

B has the structure:



wherein

α, β, χ, and δ are each independently absent or present, and when present each is a bond;

X is C or N;

Z_1 is N;

Z_2 is N or NR_7,

wherein R_7 is H, C_1-C_4 alkyl, or oxetane;

Q is a substituted or unsubstituted 5, 6, or 7 membered ring structure,

wherein

when R_1 is CF_3, R_2 is H, R_3 is F, R_4 is H, and R_5 is H, or

R_1 is H, R_2 is CF_3, R_3 is H, R_4 is CF_3, and R_5 is H, or

R_1 is Cl, R_2 is H, R_3 is H, R_4 is F, and R_5 is H, or

R_1 is CF_3, R_2 is H, R_3 is F, R_4 is H, and R_5 is H, or

R_1 is CF_3, R_2 is F, R_3 is H, R_4 is H, and R_5 is H, or

R_1 is Cl, R_2 is F, R_3 is H, R_4 is H, and R_5 is H,

then B is other than



,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1,

wherein when R_1 is CF_3, R_2 is H, R_3 is F, R_4 is H, and R_5 is H, or

R_1 is H, R_2 is CF_3, R_3 is H, R_4 is CF_3, and R_5 is H, or

R_1 is Cl, R_2 is H, R_3 is H, R_4 is F, and R_5 is H, or

R_1 is CF_3, R_2 is H, R_3 is F, R_4 is H, and R_5 is H, or

R_1 is CF_3, R_2 is F, R_3 is H, R_4 is H, and R_5 is H, or

R_1 is Cl, R_2 is F, R_3 is H, R_4 is H, and R_5 is H,

then B is other than



,

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1,

wherein

R_1 is CF_3, R_2 is F, R_3 is F, R_4 is H, and R_5 is H, or
R_1 is CF_3, R_2 is F, R_3 is H, R_4 is H, and R_5 is H, or
R_1 is CF_3, R_2 is F, R_3 is H, R_4 is F, and R_5 is H, or
R_1 is CF_3, R_2 is H, R_3 is F, R_4 is F, and R_5 is H, or
R_1 is CF_3, R_2 is H, R_3 is H, R_4 is H, and R_5 is F, or
R_1 is CF_3, R_2 is H, R_3 is F, R_4 is H, and R_5 is H, or
R_1 is CF_3, R_2 is H, R_3 is H, R_4 is Cl, and R_5 is H, or
R_1 is CF_3, R_2 is Cl, R_3 is H, R_4 is H, and R_5 is H, or
R_1 is H, R_2 is CF_3, R_3 is H, R_4 is CF_3, and R_5 is H, or
R_1 is Cl, R_2 is H, R_3 is H, R_4 is F, and R_5 is H, or
R_1 is Cl, R_2 is F, R_3 is H, R_4 is H, and R_5 is H.

4. The compound of claim 1, wherein B has the structure:



,

wherein

when α is present, then Z_1 and Z_2 are N, X is N, β is present, and χ and δ are absent; and

when α is absent, then Z_1 is N, Z_2 is N-R_7, X is C, β and δ are present, and χ is absent.

5. The compound of claim 4, wherein B has the structure:



,

wherein

n is an integer from 0-2;

α, β, χ, δ, ε, and ϕ are each independently absent or present, and when present each is a bond;

Z_1 is N;

Z_2 is N or N-R_7,

wherein R_7 is H, C_1-C_{10} alkyl, or oxetane;

X is C or N; and

Y_1, Y_2, Y_3, and each occurrence of Y_4 are each independently CR_8, CH_2, or N-R_9,

wherein

R_8 is H, halogen, OCH_3, CN, or CF_3; and

R_9 is H, CN, oxetane, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, (C_1-C_4 alkyl)(C_3-C_6 cycloalkyl), (C_1-C_6 alkyl)-OCH_3, (C_1-C_6 alkyl)-CF_3, C(O)-(C_1-C_6 alkyl), $C(O)_2$-(C_1-C_6 alkyl), C(O)-NH_2 C(O)NH-(C_1-C_6 alkyl), C(O)-(C_6 aryl), C(O)-(C_6 heteroaryl), C(O)-pyrrolidine, C(O)-piperidine, C(O)-piperazine, (C_1-C_6 alkyl)-CO_2H, (C_1-C_6 alkyl)-CO_2(C_1-C_6 alkyl) or SO_2-(C_1-C_6 alkyl).

6. The compound of claim 5, wherein B has the structure:



,

wherein

n is 0;

R_7 is H, C_1-C_4 alkyl, or oxetane;

Y_1 and Y_3 are each CH_2; and

Y_2 is N-R_9,

wherein

R_9 is H, CN, oxetane, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, (C_1-C_4 alkyl)(C_3-C_6 cycloalkyl), (C_1-C_6 alkyl)-OCH_3, (C_1-C_6 alkyl)-CF_3, C(O)-(C_1-C_6 alkyl), $C(O)_2$-(C_1-C_6 alkyl), C(O)-NH_2 C(O)NH-(C_1-C_6 alkyl), C(O)-(C_6 aryl), C(O)-(C_6 heteroaryl),

C(O)-pyrrolidine, C(O)-piperidine, C(O)-piperazine, (C_1-C_6 alkyl)-CO_2H, (C_1-C_6 alkyl)-CO_2(C_1-C_6 alkyl) or SO_2-(C_1-C_6 alkyl); or

B has the structure:



wherein

n is 1;

R_7 is H, C_1-C_4 alkyl, or oxetane;

Y_1, Y_2 and Y_4 are each CH_2; and

Y_3 is N-R_9,

wherein

R_9 is H, CN, oxetane, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, (C_1-C_4 alkyl)(C_3-C_6 cycloalkyl), (C_1-C_6 alkyl)-OCH_3, (C_1-C_6 alkyl)-CF_3, C(O)-(C_1-C_6 alkyl), $C(O)_2$-(C_1-C_6 alkyl), C(O)-NH_2 C(O)NH-(C_1-C_6 alkyl), C(O)-(C_6 aryl), C(O)-(C_6 heteroaryl), C(O)-pyrrolidine, C(O)-piperidine, C(O)-piperazine, (C_1-C_6 alkyl)-CO_2H, (C_1-C_6 alkyl)-CO_2(C_1-C_6 alkyl) or SO_2-(C_1-C_6 alkyl); or

B has the structure:



wherein

n is 1;

R_7 is H, C_1-C_4 alkyl, or oxetane;

Y_1, Y_3 and Y_4 are each CH_2; and

Y_2 is N-R_9,

wherein

R_9 is H, CN, oxetane, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, (C_1-C_4 alkyl)(C_3-C_6 cycloalkyl), (C_1-C_6 alkyl)-OCH_3, (C_1-C_6 alkyl)-CF_3, C(O)-(C_1-C_6 alkyl), $C(O)_2$-(C_1-C_6 alkyl), C(O)-NH_2 C(O)NH-(C_1-C_6 alkyl), C(O)-(C_6 aryl), C(O)-(C_6 heteroaryl), C(O)-pyrrolidine, C(O)-piperidine, C(O)-piperazine, (C_1-C_6 alkyl)-CO_2H, (C_1-C_6 alkyl)-CO_2(C_1-C_6 alkyl) or SO_2-(C_1-C_6 alkyl).

7. The compound of claim 6, wherein B has the structure:



,


, or


.

8. The compound of claim 7,

wherein R_9 is H, CN, CH_3, CH_2CH_3, $CH_2CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, *t*-Bu, $CH_2CH(CH_3)_2$, $CH_2C(CH_3)_3$, CH_2CF_3, $CH_2CH_2CF_3$, CH_2OCH_3, $CH_2CH_2OCH_3$,



,


,

,


,

SO_2-CH_3, C(O)-CH_3, C(O)-CH_2CH_3, C(O)-$CH_2CH_2CH_3$, C(O)-$CH(CH_3)_2$, C(O)-$CH_2CH(CH_3)_2$, C(O)-*t*-Bu, C(O)-OCH_3, C(O)-$NHCH_3$,



9. The compound of claim 6,

wherein

R_7 is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, or .

10. The compound of claim 5, wherein B has the structure:



wherein

Y_1, Y_2, Y_3 and Y_4 are each independently CR_8 or N,

wherein each R_8 is independently H, halogen, OCH_3, CN, or CF_3.

11. The compound of claim 10, wherein B has the structure:





wherein each R_8 is CN or OCH_3.

12. The compound of claim 8 having the structure:






,

,

,






















,
,
,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

or

,

or a pharmaceutically acceptable salt of the compound.

13. The compound of claim 11 having the structure:


,

,

,

,

,

,

,

,

, or

,

or a pharmaceutically acceptable salt of the compound.

14. The compound of claim 1 having the structure:


,

,

,

,

,

,






,or


,

or a pharmaceutically acceptable salt of the compound.

15. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.